![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Incanthera plc | AQSE:INC | Aquis Stock Exchange | Ordinary Share | GB00BGL7YW15 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 3.39% | 30.50 | 27.00 | 35.00 | 32.00 | 29.00 | 29.50 | 199,468 | 16:29:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMINC
RNS Number : 6996U
Incanthera PLC
30 March 2023
30 March 2023
Incanthera plc
("Incanthera" or the "Company")
Further re: Director's Dealing
The Company advises that, further to its announcement of 13 March 2023, the investment of GBP115,000 by Dr. Simon Ward, a director of the Company, has been delayed as a result of administrative reasons by Dr. Ward's pension provider's platform. As a result of the delay in remitting funds to the Company, admission of the shares subscribed for by Dr. Ward ("Investment Shares") to the AQSE Growth market ("Admission") has been postponed until such time as funds are received. The directors of the Company and Dr. Ward's pension provider are working to resolve the matter and it is expected that the investment will be able to be completed shortly.
Included in the initial application for Admission of the Investment Shares were 1,079,138 new ordinary shares, issued at the same price as the Investment Shares of 6.95 pence per share, to service providers in lieu of contractual amounts owed totalling approximately GBP75,000 ("Fee Shares"). The Company will proceed with the Admission of the Fee Shares, which will become effective at 08:00 a.m. on 30 March 2023
A further announcement will be made in due course on Admission of the Investment Shares.
Following Admission of the Fee Shares, the Company's enlarged issued share capital will comprise 77,464,166 ordinary shares of 2 pence each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
For further enquiries:
Incanthera plc:
+44 (0) 7831 www.incanthera.com 675747 Tim McCarthy, Chairman tim.mccarthy@incanthera.com +44 (0) 7747 625506 Simon Ward, Chief Executive Officer simon.ward@incanthera.com +44 (0) 7776 Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com 234600 Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP +44 (0) 20 Jo Turner/Ludo Lazzaretti 7213 0880 Broker: Stanford Capital Partners Ltd +44 (0) 20 Patrick Claridge/Tom Price/John Howes/Bob Pountney 3650 3650
Notes to Editors
Incanthera is dedicated to innovative technologies in dermatology and oncology. It seeks to identify and commercialise inspirational therapeutics combined with uniquely targeted delivery systems, for innovative solutions to clinical, commercially relevant unmet needs.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering Sol to a commercial partner.
Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXFFFSFVSIAFIV
(END) Dow Jones Newswires
March 30, 2023 02:00 ET (06:00 GMT)
1 Year Incanthera Chart |
1 Month Incanthera Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions